Journal Review in Hepatobiliary Surgery: ctDNA & Colorectal Liver Metastasis

Circulating tumor DNA, more commonly referred to as ctDNA, has emerged as an attractive and potentially highly sensitive biomarker for patients with colorectal cancer. But what exactly is ctDNA, does it have any prognostic value for patients with colorectal liver metastasis, and how can it be incorporated into the management of said patients? In this episode from the HPB team at Behind the Knife, listen in on the discussion about ctDNA and its role in the perioperative management of colorectal liver metastasis. 

Target Audience

  • Nurses
  • Nurse Practitioners 
  • Physicians
  • Physician Assistants

Learning Objectives

  • Developing an understanding of what circulating tumor DNA (ctDNA) is.
  • Developing an understanding of what makes ctDNA unique from other “tumor markers” like CEA.
  • Developing an understanding of the prognostic value of ctDNA for colorectal liver metastasis (CRLM).
  • Developing an understanding of the current role of ctDNA in the perioperative treatment of patients with CRLM.
  • Developing an understanding of how ctDNA can be incorporated into future treatment algorithms for patients undergoing hepatic resection for CRLM.
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 ANCC
  • 0.75 Attendance
  • 0.75 JA Credit - AH
    • 0.75 Approved for AMA PRA Category 1 Credit(s)™
Registration Opens: 
07/15/2024
Registration Expires: 
07/14/2026
Part of: 
BEHIND THE KNIFE (ENDURING)
Rating: 
0
Durham, NC 27705
United States
  • Kelly Daus 
  • Jed Gorden
  • Peter White 
  • Brian Louie
  • AMA PRA Category 1 Credit(s)
  • ANCC
  • Attendance
  • JA Credit - AH

Available Credit

  • 0.75 AMA PRA Category 1 Credit(s)™
  • 0.75 ANCC
  • 0.75 Attendance
  • 0.75 JA Credit - AH
    • 0.75 Approved for AMA PRA Category 1 Credit(s)™
Please login or register to take this course.